1. Scrip

Tech Transfer Roundup: Coronavirus Research Collaborations Respond To Pandemic

 
• By Joseph Haas

Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.

Tech Transfer regular column feature image

Privately held Ridgeback Biotherapeutics LP and Emory Universityy announced on 19 March they will work together to advance EIDD-2801 – an oral ribonucleoside analog that can inhibit replication of RNA viruses – for COVID-19. No terms were disclosed but Ridgeback gets a license to EIDD-2801 and said it will take the molecule through clinical development for the virus and be responsible for making the therapy available during the pandemic.

Under an agreement signed between Ridgeback and Drug Innovations at Emory LLC (DRIVE), a non-profit company affiliated with the university, Ridgeback will employ what it learned in developing mAB114 (ansuvimab) for Ebola virus during the 2018 outbreak in the Democratic Republic of Congo

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 
• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.